Pfizer announces positive topline results from Phase 3 study of Hemophilia B gene therapy candidate

Enhertu to demonstrate a significant survival benefit vs. chemotherapy

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years

Emmes launches Cell and Gene Therapy Center

The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials

Merck gets fast track designation from the USFDA for anticoagulant therapy

Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

Brii Bio inks partnership with China Resources Pharmaceutical to advance the commercialization of Long-acting COVID-19 neutralizing antibody therapy

The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China

Biologicals have emerged as a therapy of choice where traditional chemical drugs fail: Dr Bharati Pravin Pawar

National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries